News

GST Restructuring in Auto Sector: What 40% Flat Rate Means for Automakers

Simpler on Paper, Complex in Practice: Auto Industry Faces New GST Framework

GST

The GST Council’s recent decision to overhaul tax rates has triggered a major shift for India’s automobile sector. By replacing the four-tier system with a leaner two-tier structure, the government aims to cut complexity and bring more clarity.

For automakers, however, the move comes with fresh challenges. The Compensation Cess on vehicles has been discontinued, while the base GST rate has been raised from 28% to 40%. The government hopes this balances revenue needs with tax simplification, but the industry is left grappling with unanswered questions around pricing, compliance, and unutilised Cess credits.

From 50% to 40%: A Reshaped Tax Structure

When GST was introduced in 2017, automobiles fell into the highest slab — 28% GST plus a Compensation Cess of up to 22%, taking the total incidence close to 50%.

The Cess, originally temporary, was repeatedly extended to help states, even during the pandemic. Now, with most obligations met, the Council has opted for a flat 40% GST rate and removed the Cess.

On paper, that means a tax cut — from nearly 50% to 40%.

The Pricing Dilemma

This raises a key question: must automakers pass the benefit to consumers?

  • Section 171 of the CGST Act requires that tax cuts be passed on.

  • But the provision only mentions GST, not Cess. The Compensation Cess Act never had anti-profiteering rules built in.

  • Legally, businesses can argue that the end of Cess doesn’t require price reductions, especially since the GST base rate has gone up at the same time.

However, a counter-argument exists: since Cess was part of the overall tax burden, its removal should reduce costs for consumers. This clash of interpretations creates uncertainty, with companies balancing legal grounds against market expectations.

Neutralisation or Real Benefit?

The effective tax has dropped from 50% to 40%. But automakers argue the higher GST base rate, combined with stranded Cess credits, neutralises much of the relief.

The biggest concern: what happens to accumulated Cess credits?

  • Since Cess is discontinued, these credits can no longer be used.

  • Legally, no reversal seems required, as Cess is not “exempt” but simply withdrawn.

  • Still, with no transitional provisions or refunds, the credits become stranded costs — eroding the real benefit for businesses.

Implications for Automakers

  1. Compliance Risks – Scrutiny over whether price benefits are passed on, despite unclear laws.

  2. Pricing Strategy – Balancing consumer expectations with rising input costs and stranded credits.

  3. Litigation Potential – Disputes likely over Cess credit treatment and profiteering obligations.

  4. Structural Simplification – In the long run, a single GST rate promises predictability and transparency.

Navigating the Road Ahead

The rationalisation is a welcome step towards simplification, but its execution leaves grey areas. Automakers now face:

  • Unclear rules on passing benefits,

  • Loss of accumulated credits,

  • Risk of disputes with regulators and consumers.

Until the government issues clear guidance, companies must tread carefully. While the long-term effect could be a simpler, more transparent tax regime, in the short term, the auto industry is navigating a complex and uncertain road.

Read More: marketstatsinsight.com

Principal Consultant at Market Stats Insight
Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.
Rohan

Rohan

Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.